Advances in Genetic Profile and Therapeutic Strategy of Pulmonary Large Cell Neuroendocrine Carcinoma

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Mar 14

PMID 38482526

Authors

Siyu Zhu

Xinyue Wang

Hui Li

Peiyan Zhao

Jingjing Liu

Liang Zhang

Ying Cheng

Affiliations

Soon will be listed here.

Abstract

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma (HGNEC) accounting for 3% of primary lung cancer, and characterized by strong invasion, high heterogeneity, and extremely poor prognosis. At present, the diagnosis and treatment of LCNEC remains controversial and refer to therapeutic strategy of small cell lung cancer (SCLC), lacking precise therapy. Recently, the genetic analysis and clinical trials of LCNEC gradually emerged, providing more evidence for precise diagnosis and treatment. Here, we review the diagnosis, molecular characteristics, and treatment of LCNEC based on the existing research and frontier progress to provide a potential direction for future diagnosis and treatment of LCNEC.

References

Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E . Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 2020; 143:40-46. DOI: 10.1016/j.lungcan.2020.03.008. View

De Pas T, Giovannini M, Manzotti M, Trifiro G, Toffalorio F, Catania C . Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011; 29(34):e819-22. DOI: 10.1200/JCO.2011.36.2251. View

Dudnik E, Kareff S, Moskovitz M, Kim C, Liu S, Lobachov A . Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J Immunother Cancer. 2021; 9(2). PMC: 7893659. DOI: 10.1136/jitc-2020-001999. View

Karlsson A, Jonsson M, Lauss M, Brunnstrom H, Jonsson P, Borg A . Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome. Clin Cancer Res. 2014; 20(23):6127-40. DOI: 10.1158/1078-0432.CCR-14-1087. View

Bari M, Brown H, Nicholson A, Kerr K, Gosney J, Wallace W . BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas. Histopathology. 2013; 64(4):547-56. DOI: 10.1111/his.12278. View

Han Y, Pang L, Huang J, Chen J . Large cell neuroendocrine carcinoma of the lungs: case report and literature review. Ann Palliat Med. 2020; 9(5):3705-3709. DOI: 10.21037/apm-20-1667. View

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L . Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022; 33(1):115-154. DOI: 10.1007/s12022-022-09708-2. View

Chen Y, Zhang J, Huang C, Tian Z, Zhou X, Guo C . Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review. Orphanet J Rare Dis. 2021; 16(1):82. PMC: 7881654. DOI: 10.1186/s13023-021-01730-7. View

Christopoulos P, Schneider M, Bozorgmehr F, Kuon J, Engel-Riedel W, Kollmeier J . Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. Lung Cancer. 2018; 119:48-55. DOI: 10.1016/j.lungcan.2018.03.002. View

10.

Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K . Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006; 82(5):1802-7. DOI: 10.1016/j.athoracsur.2006.05.109. View

11.

Peng W, Cao L, Chen L, Lin G, Zhu B, Hu X . Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). Oncologist. 2022; 27(2):e116-e125. PMC: 8895731. DOI: 10.1093/oncolo/oyab044. View

12.

Oda R, Okuda K, Yamashita Y, Sakane T, Tatematsu T, Yokota K . Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab. Thorac Cancer. 2020; 11(7):2036-2039. PMC: 7327674. DOI: 10.1111/1759-7714.13471. View

13.

Aroldi F, Bertocchi P, Meriggi F, Abeni C, Ogliosi C, Rota L . Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report. Case Rep Oncol. 2014; 7(2):478-83. PMC: 4154195. DOI: 10.1159/000365413. View

14.

Brominska B, Gabryel P, Jarmolowska-Jurczyszyn D, Janicka-Jedynska M, Kluk A, Trojanowski M . Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. Arch Med Sci. 2019; 15(4):1010-1016. PMC: 6657266. DOI: 10.5114/aoms.2018.75889. View

15.

Obayashi S, Horiguchi J, Higuchi T, Katayama A, Handa T, Altan B . Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol. 2017; 51(3):781-790. PMC: 5564402. DOI: 10.3892/ijo.2017.4085. View

16.

Komiya T, Ravindra N, Powell E . Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pac J Cancer Prev. 2021; 22(2):365-370. PMC: 8190341. DOI: 10.31557/APJCP.2021.22.2.365. View

17.

Zhang S, Xiao Y, Chen L, Li Z, Zong Y, Zhu K . Endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime for advanced pulmonary large-cell neuroendocrine carcinoma as a first-line treatment: A case report. Open Life Sci. 2022; 17(1):577-585. PMC: 9202532. DOI: 10.1515/biol-2022-0062. View

18.

Jiang Y, Lei C, Zhang X, Cui Y, Che K, Shen H . Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Cancer. 2019; 10(25):6422-6430. PMC: 6856741. DOI: 10.7150/jca.32446. View

19.

Ye B, Cappel J, Findeis-Hosey J, McMahon L, Yang Q, Xiao G . hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Hum Pathol. 2015; 48:142-7. DOI: 10.1016/j.humpath.2015.09.019. View

20.

Jovanoski N, Bowes K, Brown A, Belleli R, Di Maio D, Chadda S . Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence. Lung Cancer Manag. 2023; 12(3):LMT60. PMC: 10485735. DOI: 10.2217/lmt-2023-0003. View